Antibody-drug conjugates in cancer therapy

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 15-29

  Sievers, Eric L ^a   Senter, Peter D ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

chemotherapeutic; drug delivery; immunotherapy; monoclonal antibody; targeting; tumor

Indexed keywords

AGS 16M8F; ANTIBODY CONJUGATE; ASG 22ME; ASG 5ME; BAY 794620; BAY 949343; BIIB 015; BRENTUXIMAB VEDOTIN; BT 062; CYTOTOXIC AGENT; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB VEDOTIN; IMGN 529; IMMU 130; INOTUZUMAB OZOGAMICIN; LORVOTUZUMAB MERTANSINE; MDX 1203; MILATUZUMAB; RG 7593; SAR 3419; SAR 566658; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VORSETUZUMAB MAFODOTIN;

B CELL LYMPHOMA; CANCER CELL; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENCY; DRUG RELEASE; DRUG TARGETING; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; MALE; NEOPLASMS;

EID: 84873053339     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-050311-201823     Document Type: Review

References (78)

1. Reichert JM, Rosensweig CJ, Faden LB, et al. 2005. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23:1073-78
2. Senter PD. 2009. Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol. 13:235-44
3. Teicher BA, Chari RV. 2011. Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res. 17:6389-97
4. Chari RV. 2008. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41:98-107
5. Wahl AF, Klussman K, Thompson JD, et al. 2002. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest andDNAfragmentation in vitro and affects antitumor activity inmodels of Hodgkin's disease. Cancer Res. 62:3736-42
6. Stein H, Foss HD, Durkop H, et al. 2000. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96:3681-95
7. Falini B, Pileri S, Pizzolo G, et al. 1995. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1-14
8. Francisco JA, Cerveny CG, Meyer DL, et al. 2003. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458-65
9. Oflazoglu E, Kissler KM, Sievers EL, et al. 2008. Combination of the anti-CD30-auristatin-E antibodydrug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br. J. Haematol. 142:69-73
10. Lewis Phillips GD, Li G, Dugger DL, et al. 2008. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68:9280-90
11. Younes A, Gopal AK, Smith SE, et al. 2012. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 30:2183-89
12. Pro B, Advani R, Brice P, et al. 2012. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: results of a phase 2 study. J. Clin. Oncol. 30:2190-96
13. Krop IE, Beeram M, Modi S, et al. 2010. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28:2698-704
14. Law CL, Cerveny CG, Gordon KA, et al. 2004. Efficient elimination of B-lineage lymphomas by anti- CD20-auristatin conjugates. Clin. Cancer Res. 10:7842-51
15. Smith LM, Nesterova A, Alley SC, et al. 2006. Potent cytotoxicity of an auristatin-containing antibodydrug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol. Cancer Ther. 5:1474-82
16. Alley SC, Zhang X, Okeley NM, et al. 2009. The pharmacologic basis for antibody-auristatin conjugate activity. J. Pharmacol. Exp. Ther. 330:932-38
17. Thurber GM, Schmidt MM, Wittrup KD. 2008. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 60:1421-34
18. Bross PF, Beitz J, Chen G, et al. 2001. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7:1490-96
19. Sievers EL. 2003. Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). Blood Cells Mol. Dis. 31:7-10
20. Slamon DJ, Leyland-Jones B, Shak S, et al. 2001. Use of chemotherapy plus amonoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783-92
21. Junttila TT, Li G, Parsons K, et al. 2010. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 128:347-56
22. Mao W, Luis E, Ross S, et al. 2004. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res. 64:781-88
23. Erickson HK, Widdison WC, Mayo MF, et al. 2010. Tumor delivery and in vivo processing of disulfidelinked and thioether-linked antibody-maytansinoid conjugates. Bioconjug. Chem. 21:84-92
24. Hamann PR, Hinman LM, Hollander I, et al. 2002. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13:47-58
25. Boghaert ER, Khandke KM, Sridharan L, et al. 2008. Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples. Cancer Chemother. Pharmacol. 61:1027-35
26. Sanderson RJ, Hering MA, James SF, et al. 2005. In vivo drug-linker stability of an anti-CD30 dipeptidelinked auristatin immunoconjugate. Clin. Cancer Res. 11:843-52
27. Senter P, Sievers EL. 2012. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 30:631-37
28. Erickson HK, Park PU, Widdison WC, et al. 2006. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66:4426-33
29. Doronina SO, Mendelsohn BA, Bovee TD, et al. 2006. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug. Chem. 17:114-24
30. Hamblett KJ, Senter PD, Chace DF, et al. 2004. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10:7063-70
31. Carter D. 2008. The neuroendocrine tumors of the lung, 1926-1998: some historical observations. Semin. Diagn. Pathol. 25:154-65
32. Alley SC, Okeley NM, Senter PD. 2010. Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14:529-37
33. Doronina SO, Toki BE, Torgov MY, et al. 2003. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21:778-84
34. Thorson JS, Sievers EL, Ahlert J, et al. 2000. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr. Pharm. Des. 6:1841-79
35. Katz J, Janik JE, Younes A. 2011. Brentuximab vedotin (SGN-35). Clin. Cancer Res. 17:6428-36
36. Smith S, Chen R, Gopal A, et al. 2012. Long-term follow-up results of an ongoing pivotal study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL). Eur. Hematol. Assoc. Annu. Meet. Abstr., Abstr. 1109
37. Horning S, Fanale M, deVos S, et al. 2008. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. Ann. Oncol. 19:118
38. LoRusso PM, Weiss D, Guardino E, et al. 2011. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res. 17:6437-47
39. Hurvitz S, Dirix L, Kocsis J, et al. 2011. ORAL trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T) in previously-untreated HER2-positivemetastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). Eur. Multidiscip. Cancer Congr., Abstr. 5001
40. Blackwell KL, Miles D, Gianni L, et al. 2012. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and taxane. J. Clin. Oncol. Meet. Abstr., Abstr. LBA1
41. Ricart AD. 2011. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin. Cancer Res. 17:6417-27
42. Sievers EL, Larson RA, Stadtmauer EA, et al. 2001. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19:3244-54
43. Giles FJ, Kantarjian HM, Kornblau SM, et al. 2001. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92:406-13
44. Rajvanshi P, Shulman HM, Sievers EL, et al. 2002. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 99:2310-14
45. Petersdorf S, Kopecky K, Stuart RK, et al. 2009. Preliminary results of SouthwestOncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Am. Soc. Hematol. Annu. Meet. Abstr., Abstr. 790
46. Burnett AK, Hills RK, Milligan D, et al. 2011. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J. Clin. Oncol. 29:369-77
47. Ravandi F. 2011. Gemtuzumab ozogamicin: one size does not fit all-the case for personalized therapy. J. Clin. Oncol. 29:349-51
48. Burnett AK, Hills RK, Hunter AE, et al. 2011. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial. Am. Soc. Hematol. Annu. Meet. Abstr., Abstr. 582
49. Castaigne S, Pautas C, Terré C, et al. 2012. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379:1508-16
50. Mason DY, Stein H, Gerdes J, et al. 1987. Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells. Blood 69:836-40
51. Olejniczak SH, Stewart CC, Donohue K, et al. 2006. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol. Invest. 35:93-114
52. Advani A, Coiffier B, Czuczman MS, et al. 2010. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J. Clin. Oncol. 28:2085-93
53. Vaickus L, Ball ED, Foon KA. 1991. Immune markers in hematologic malignancies. Crit. Rev. Oncol. Hematol. 11:267-97
54. Kantarjian H, Thomas D, Jorgensen J, et al. 2012. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 13:403-11
55. Kebriaei P, Wilhelm K, Ravandi F, et al. 2011. Inotuzumab ozogamicin (IO) is an effective salvage therapy that allows for allogeneic hematopoietic stem cell transplantation (HSCT) in remission in patients with advanced acute lymphoblastic leukemia (ALL). Am. Soc. Hematol. Annu. Meet. Abstr., Abstr. 3102
56. Rose AA, Grosset AA, Dong Z, et al. 2010. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin. Cancer Res. 16:2147-56
57. Hamid O, Sznol M, Pavlick AC, et al. 2010. Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. Am. Soc. Clin. Oncol. Meet. Abstr., Abstr. 8525
58. Saleh MN, Bendell JC, Rose A, et al. 2010. Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody-drug conjugate (ADC), CDX-011 (CR011-vcMMAE). Am. Soc. Clin. Oncol. Meet. Abstr., Abstr. 1095
59. Coiffier B, Ribrag V, Dupuis J, et al. 2011. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Am. Soc. Clin. Oncol. Meet. Abstr., Abstr. 8017
60. Beck A, Senter P, Chari R. 2011. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. MAbs 3:331-37
61. Hartley JA, Hamaguchi A, Coffils M, et al. 2010. SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity. Cancer Res. 70:6849-58
62. Moldenhauer G, Salnikov AV, Luttgau S, et al. 2012. Therapeutic potential of amanitin-conjugated antiepithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J. Natl. Cancer Inst. 104:622-34
63. Junutula JR, Raab H, Clark S, et al. 2008. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26:925-32
64. Carter PJ, Senter PD. 2008. Antibody-drug conjugates for cancer therapy. Cancer J. 14:154-69
65. Shen BQ, Xu K, Liu L, et al. 2012. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30:184-89
66. Friedman M, Nordberg E, Höidén-Guthenberg I, et al. 2007. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng. Des. Sel. 20:189-99
67. Kim KM, McDonagh CF, Westendorf L, et al. 2008. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol. Cancer Ther. 7:2486-97
68. Leonard JP, Coleman M, Ketas JC, et al. 2003. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 21:3051-59
69. Goy A, Leach J, Ehmann WC, et al. 2010. Inotuzumab ozogamicin (CMC-544) in patients with indolent B-cell NHL that is refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy: preliminary safety and efficacy from a phase 2 trial. Am. Soc. Hematol. Annu. Meet. Abstr., Abstr. 430
70. Forero-Torres A, Leonard JP, Younes A, et al. 2009. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br. J. Haematol. 146:171-79
71. Raza A, Jurcic JG, Feldman EJ, et al. 2009. Prolonged exposure to lintuzumab monotherapy in acute myeloid leukemia and myelodysplastic syndromes-results of a phase 1 trial. Eur. Hematol. Assoc. Annu. Meet. Abstr., Abstr. 833
72. Larson RA, Sievers EL, Stadtmauer EA, et al. 2005. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104:1442-52
73. Cobleigh MA, Vogel CL, Tripathy D, et al. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:2639-48
74. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. 2005. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J. Clin. Oncol. 23:2162-71
75. Vogel CL, Cobleigh MA, Tripathy D, et al. 2002. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20:719-26
76. Burris HA 3rd, Rugo HS, Vukelja SJ, et al. 2011. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29:398-405
77. Krop I, Lorusso P, Miller K, et al. 2010. A phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, lapatinib, and chemotherapy. Eur. Soc. Med. Oncol. Meet. Abstr., Abstr. 5082
78. Cortes J, Baselga J, Petrella T, et al. 2009. Pertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advancedHER2-positive breast cancer. Am. Soc. Clin. Oncol. Meet. Abstr., Abstr. 1022